RxDoctor Payments Data

Christine Atkinson, APRN

Psychiatric/Mental Health · Vero Beach, FLNPI 1407123813

Payments from drug & device makers

$2,398in general payments, 2019–2025

Across 96 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$416
  • Johnson & Johnson$358
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$345
  • Otsuka America Pharmaceutical, Inc.$338
  • Teva Pharmaceuticals USA, Inc.$305
  • Alkermes, Inc.$243
  • plus $392 from 5 others

What the payments were for

  • Food & beverage$2,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,398 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$17,007
Medicare patients
35
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$52,833
LybalviOlanzapine/Samidorphan Malate11$17,985
Lurasidone Hcl11$4,224
Ziprasidone Hcl11$2,658
Quetiapine Fumarate87$1,322
Bupropion XlBupropion Hcl57$968
Aripiprazole33$903
Gabapentin36$845
Fluoxetine Hcl67$663
Buspirone Hcl35$604
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$589
Lamotrigine44$533
Hydroxyzine Hcl20$465
Trazodone Hcl38$363
Olanzapine24$318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$305$52,83311 claims
Alkermes, Inc.Lybalvi$243$17,98511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →